ArticleTherapeutic advances in endocrinology and metabolism2026
Thyroid function alterations after radiofrequency ablation in benign thyroid nodule management.
Article in Therapeutic advances in endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiofrequency ablation (RFA) has gained recognition as a highly effective treatment for benign thyroid nodules (BTNs). However, post-procedural thyroid function changes have been reported. Objectives: This study specifically focuses on the potential link between changes in thyroid function and the volume reduction ratio (VRR) of treated nodules. Additionally, it seeks to evaluate whether fluctuations in thyroid function at mid-term follow-up can serve as early indicators for the development of long-term hypothyroidism following RFA. Design: Retrospective cohort study. Methods: In this study, 50 euthyroid individuals (mean age = 47.1 years; 43 females, 7 males) with a total of 72 BTNs (median volume = 4.61 mL) undergoing RFA were evaluated. Comprehensive assessments, including clinical examinations, ultrasound imaging, and blood tests, were conducted at specific intervals (pre-RFA, and at 6 months, 12 months, and annually post-RFA). Results: The mean follow-up period was 22.3 months. Both medium-term and long-term follow-ups revealed significant reductions in triiodothyronine (T3) levels ( Conclusion: Following RFA, notable alterations in thyroid function were observed, without meeting the criteria of hypothyroidism. Additionally, a lower mid-term T3 level may be indicative of a better VRR during long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.